The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | CLL advances: What will we see more of in 2021?
John Seymour, MBBS, FRACP, Peter MacCallum Cancer Centre, East Melbourne, Australia, discusses exciting advances in chronic lymphocytic leukemia (CLL) presented at ASH 2020. He notes a strong theme of increased exploration of novel-novel combinations. However, Prof. Seymour believes that longer-term follow-up and an improved understanding of the impact of sequencing are vital for the validation of these therapies. Advances in cellular therapies and non-covalent BTK inhibitors are highlighted as major advances that will have a greater role in the coming years. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
